CD274 and renal cell carcinoma: Riaz 2017, GSE91061, Figure 10D, p = 0.032), advanced urothelial cancer who received anti-PD-L1 therapy (IMvigor210CoreBiologies, Figure 10E, p = 0.0097), and advanced renal cell carcinoma who were treated with Avelumab (anti-PD-L1) plus axitinib versus sunitinib (The phase III JAVELIN Renal 101 trial, NCT02684006, Figure 10F, p = 0.012) were included in the study.